ENZALUTAMIDE AND OVERALL SURVIVAL IN PATIENTS WITH PROSTATE CANCER AFTER CHEMOTHERAPY

Authors

  • Jurayev Shakhzod Shavkatovich Saint Petersburg State Pediatric Medical University

Keywords:

Enzalutamide; castration-resistant prostate cancer; survival; chemotherapy; clinical efficacy.

Abstract

Enzalutamide (MDV3100), an androgen receptor signaling pathway inhibitor, was investigated in an international phase III randomized trial involving 1,199 patients with castration-resistant prostate cancer after chemotherapy. Administration of enzalutamide at a dose of 160 mg/day significantly increased overall survival compared with placebo (18.4 vs. 13.6 months; HR 0.63; p<0.001) and demonstrated superiority across all secondary endpoints, including reduction in PSA levels, objective tumor response, improvement in quality of life, and prolonged time to progression. The main adverse events were fatigue, diarrhea, and hot flashes, with seizures observed in rare cases. These findings confirm the significant clinical efficacy of enzalutamide in patients with metastatic castration-resistant prostate cancer following chemotherapy.

Downloads

Download data is not yet available.

References

Scher HI, Sawyers CL. Biology of progressive castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253–61.

Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res. 2011;17:1649–57.

Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.

Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–46.

de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11:459–76.

Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217–27.

Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401–6.

Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.

Downloads

Published

2025-09-24

How to Cite

Jurayev Shakhzod Shavkatovich. (2025). ENZALUTAMIDE AND OVERALL SURVIVAL IN PATIENTS WITH PROSTATE CANCER AFTER CHEMOTHERAPY. Journal of Applied Science and Social Science, 15(09), 858–863. Retrieved from https://www.internationaljournal.co.in/index.php/jasass/article/view/1894

Issue

Vol. 15 No. 09 (2025): Volume 15 Issue 09

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.